Volume 3 Supplement 1

EAACI International Severe Asthma Forum (ISAF 2012): Abstracts

Open Access

Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting

  • Gert-Jan Braunstahl1,
  • Marco Deenstra2,
  • Janice Canvin3,
  • Guy Peachey3,
  • Chien-Wei Chen4,
  • Panayiotis Georgiou3 and
  • Robert Maykut5
Clinical and Translational Allergy20133(Suppl 1):P1

DOI: 10.1186/2045-7022-3-S1-P1

Published: 3 May 2013

Background

With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden. The cost of treating uncontrolled severe allergic asthma (SAA) is high encompassing a variety of direct medical costs and indirect costs. We present data on real-world healthcare utilization (direct) and school/work absence (indirect) in uncontrolled SAA patients receiving omalizumab in the eXpeRience registry.

Methods

eXpeRience was a 2-year, global, single-arm, observational registry. Data were collected on real-world effectiveness, safety and use of omalizumab in patients with uncontrolled SAA. Asthma-related healthcare utilization (hospitalizations, emergency room visits or unscheduled doctor visits) and number of days missed from school/work were recorded.

Results

The intent-to-treat population comprised 916 (97.1%) patients. Compared with the pre-treatment period, there were reductions in healthcare utilization and school/work absence after 12 and 24 months of omalizumab treatment.

Table 1

Variable, mean (SD); n

Pre-treatment° (N=916)

12 months (N=734)

24 months (N=643)

Asthma-related hospitalizations

0.7 (1.32); 882

0.1 (0.43); 702

0.1 (0.41); 628

Duration of hospitalization stay due to asthma, days

5.3 (11.05); 852

0.7 (3.84); 703

0.5 (3.39); 628

Asthma-related emergency room visits

1.8 (2.87); 867

0.2 (0.64); 700

0.1 (0.32); 627

Unscheduled asthma-related doctor visits

3.8 (4.79); 823

0.7 (1.43); 684

0.4 (0.99); 619

Asthma-related medical healthcare uses*

6.2 (6.97); 811

1.0 (1.96); 684

0.5 (1.28); 618

Absence from work due to asthma#, days

26.4 (49.61); 347

3.5 (17.28); 295

1.0 (4.66); 296

Absence from school due to asthma#, days

20.7 (27.49); 57

1.6 (4.28); 59

1.9 (5.46); 58

Table 1 shows annualized data (12 month combined 16 weeks, 8 and 12 month data; 24 month combined 18 and 24 month data).

n number of patients with data recorded. ° Within 12 months prior to start of omalizumab treatment. *Total number of asthma-related healthcare uses was calculated if data for asthma-related hospitalizations, emergency room visits and unscheduled doctor visits were available. #Excluded those patients for whom this category was not applicable. Conclusion: Results from the eXpeRience registry showed that omalizumab reduced healthcare utilization and the number of days missed from school or work by asthma patients in a real-world setting. Thus, omalizumab treatment was associated with a positive and substantial impact on the direct and indirect costs linked with uncontrolled SAA.

Authors’ Affiliations

(1)
St Franciscus Gasthuis, Department of Pulmonary Medicine
(2)
Flevoziekenhuis, Department of Pulmonology
(3)
Novartis Pharmaceuticals UK Limited, Clinical Development
(4)
Novartis Pharmaceuticals Corporation, Clinical Development
(5)
Novartis Pharma AG, Clinical Development

Copyright

© Braunstahl et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement